Non-alcoholic fatty liver disease (NAFLD) is the largest chronic liver disease in the world with the prevalence estimated to be approximately 30% of adults in developed countries such as Australia and the United States. There are currently no drugs available for it's treatment.
This study is looking at potential new treatment for non-alcoholic fatty liver disease (NAFLD). The purpose of this study is to investigate the safety and tolerability of this new medication in healthy participants and how it is absorbed and processed by the body.
The trial has been approved by an independent ethics committee and you will be reimbursed for your time.